Issue 85, 2013

Synthetic modification of salinomycin: selective O-acylation and biological evaluation

Abstract

Salinomycin has found renewed interest as an agent for prevention of cancer recurrence through selectively targeting cancer stem cells. Strategies for generation of improved salinomycin analogs by individual modification of its hydroxyl groups are presented. An evaluation of the dose–response effects of the resulting library on breast cancer cell lines shows that acylation of the C20 hydroxyl can be used to improve IC50 values down to one fifth that of salinomycin.

Graphical abstract: Synthetic modification of salinomycin: selective O-acylation and biological evaluation

Supplementary files

Article information

Article type
Communication
Submitted
05 Aug 2013
Accepted
21 Aug 2013
First published
03 Sep 2013
This article is Open Access
Creative Commons BY license

Chem. Commun., 2013,49, 9944-9946

Synthetic modification of salinomycin: selective O-acylation and biological evaluation

B. Borgström, X. Huang, M. Pošta, C. Hegardt, S. Oredsson and D. Strand, Chem. Commun., 2013, 49, 9944 DOI: 10.1039/C3CC45983G

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements